Oppenheimer initiated coverage on Abbott Labs with a new price target
$ABT
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $130.00 | Outperform | Oppenheimer |
| 9/19/2024 | $131.00 | Overweight | Piper Sandler |
| 7/30/2024 | Buy → Hold | Edward Jones | |
| 5/30/2024 | $121.00 | Buy | Goldman |
| 7/21/2023 | Underperform → Peer Perform | Wolfe Research | |
| 5/30/2023 | $112.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/20/2023 | $125.00 → $127.00 | Overweight | Barclays |
| 4/20/2023 | $107.00 → $103.00 | Underperform | Wolfe Research |
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 405th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billionFourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024. Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and 10.1 percent on an organic basis
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,
144 - ABBOTT LABORATORIES (0000001800) (Subject)
10-K - ABBOTT LABORATORIES (0000001800) (Filer)
144 - ABBOTT LABORATORIES (0000001800) (Subject)
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE:ABT) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the terms of the Collaboration and Data Sharing Agreement, Abbott will sup
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 405th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00
Edward Jones downgraded Abbott Labs from Buy to Hold
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)